特瑞思药业

Teruisi Biopharma is a clinical-stage biotechnology company based in Huzhou, China, dedicated to the development and commercialization of high-quality biologics. The company focuses on two main tracks: high-entry-barrier biosimilars and innovative antibody-drug conjugates (ADCs) for oncology and metabolic diseases. Teruisi operates a large-scale manufacturing facility that adheres to international GMP standards, featuring multiple 2,000-liter bioreactors to support global clinical trials and commercial supply. Its lead programs include biosimilars for bevacizumab and denosumab, both of which have reached late-stage clinical development. By integrating advanced R&D with robust manufacturing capabilities, Teruisi aims to provide affordable and effective therapeutic solutions to patients worldwide.